Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

PharmaCyte Biotech (PMCB) Debt to Equity (2020 - 2021)

PharmaCyte Biotech (PMCB) has disclosed Debt to Equity for 6 consecutive years, with $0.02 as the latest value for Q1 2021.

  • On a quarterly basis, Debt to Equity changed N/A to $0.02 in Q1 2021 year-over-year; TTM through Jan 2021 was $0.02, a N/A change, with the full-year FY2020 number at $0.01, changed N/A from a year prior.
  • Debt to Equity was $0.02 for Q1 2021 at PharmaCyte Biotech, up from $0.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.02 in Q3 2020 to a low of $0.01 in Q2 2020.